Citius Pharmaceuticals is trading at $0.73 (-6.5%) in pre-market action, easing after a significant multi-day rally.
- The stock is experiencing profit-taking and consolidation following its recent sharp upward move.
- The previous rally was fueled by positive commercial updates for LYMPHIR, which included strong quarterly growth in new accounts.